BLAINJECTIONINJECTABLEPriority Review
Approved
Dec 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
51
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 13h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BLINCYTO (blinatumomab) is a bispecific antibody that engages T cells to target and eliminate B cells expressing CD19, primarily used in relapsed or refractory acute lymphoblastic leukemia (ALL). It bridges the patient's immune system to cancer cells, creating a novel mechanism for hematologic malignancy treatment. The drug represents a shift toward immunooncology strategies in ALL management.
$0.002BPart D
PeakProduct at peak lifecycle stage with modest Part D penetration (61 claims in 2023) suggests mature commercial organization with potential for selective specialization rather than broad field expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (51)
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
Started Nov 2026
20 enrolled
BlinatumomabRevumenibLymphoblastic Leukemia+1 more
A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)
Started Oct 2026
26 enrolled
Philadelphia Positive Acute Lymphoblastic Leukemia
Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia
Started Sep 2026
40 enrolled
Phase 2 StudyBlinatumomabAcute Lymphoblastic Leukemia
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
Started Aug 2026
60 enrolled
Phase II Clinical TrialBlinatumomabOlverembatinib+2 more
Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL
Started Jul 2026
80 enrolled
Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)BCR-ABL Positive Acute Lymphoblastic Leukemia
Worked on BLINCYTO at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.